Here, we show that SEMA3C is a secreted soluble autocrine growth factor that drives growth and treatment resistance of prostate cancer via activation of multiple RTKs such as EGFR, MET, and ErbB2 in a cognate ligand‐independent manner. This evidence concerns the gene ERBB2 and prostate carcinoma.